A $5 million jury verdict was handed down in the first of the federal multidistrict litigation cases involving patients claiming injury from the body scan contrast agent gadolinium. The Ohio jury found GE Healthcare chose not to provide the necessary health risk warnings with patients with impaired kidney function when gadolinium is used in a body scan. The gadolinium product is a contrast dye used in MRI and other radiographic scanning.
The plaintiff in this case developed an untreatable skin disease called nephrogenic systemic fibrosis (NSF) as a result of being injected with the Omniscan for magnetic resonance angiogram. Omniscan is the prescription medication with gadolinium as a product that is used to screen patients for acute kidney injury or other conditions related to reduced renal function.
The drug makers of the Omniscan product, GE Healthcare, Bayer and Covidien have defended hundreds of lawsuits claiming injuries from the gadolinium-based contrast agent products.